Neurotransmitter Articles & Analysis
20 news found
Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, database construction, and other related data analysis services utilizing comprehensive technology. The Product Manager at CD Genomics is pleased to announce the launch of the LC-MS/MS Data Analysis service, enabling high-performance, regulated ...
Cosmetic peptide synthesis and production is now attached much attention by BOC Sciences officials to meet the increasing demand for cosmetic applications. Peptides are publicly accepted as promising cosmetic compounds with prominent roles in collagen production, anti-wrinkle activity, pigmentation reduction, firming, etc. BOC Sciences is equipped with years of experience and versatile ...
Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The trial, MOOD, will assess the ...
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and ...
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of ...
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other ...
ByVaxxinit
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy. The data are being ...
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona Therapeutics, a clinical-stage biotherapeutics ...
Ahead of their attendance at this year’s MEDICA event, AgPlus have appointed a new Chief Scientific Officer, Dr Nic Christofides, who has vast experience of finalising late stage clinical assays to ensure commercial success. Of Cypriot descent, Dr Christofides started his career in 1973 at Hammersmith Hospital, London, as a research assistant where he developed immunoassay for Oestriol ...
Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system. Relivion® is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits ...
Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan. Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled ...
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. A wearable device, the Relivion®DP system is designed as an adjunctive treatment to pharmaceutical ...
Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. These include biomarkers indicating that altered neurotransmission, energy metabolism, and ...
New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that researchers will present an expanded analysis of data from the company’s Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual desire disorder (HSDD) based on the Patient Global Impression of Change (PGIC) scale. Robert E. Pyke, MD, PhD, president of Pykonsult, LLC, ...
New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that the company will participate in a panel discussion, “Innovation Across Borders: Strategies for U.S. and Chinese Companies in the Health Sciences Industry,” to be hosted by Duane Morris LLP and the Chinese Biopharmaceutical Association (USA) on Tuesday, January 8, 2019 in San Francisco, CA. The ...
New York, NY – December 20, 2018 – S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company’s proprietary dual-mechanistic therapy Lorexys™ for hypoactive sexual desire disorder. A corresponding patent was previously granted in several countries in Asia including China, Japan, South Korea, and Singapore. The EU ...
NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, and CKD Pharmaceuticals, a leading pharmaceutical company in South Korea, today announced that they have entered into a commercialization agreement for Lorexys™, S1 ...
NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, today announced that Nicolas Sitchon, CEO of S1 Biopharma, will present at the BIO-Europe 2015 Conference on Tuesday, November 3, 2015 at the International Congress Center in Munich, ...
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...